Anbogen Therapeutics, Inc., a Taipei, Taiwan-based clinical-stage company developing cancer therapies, raised USD 7.3M in Series A+ funding.
The round was led by KGI Venture Capital and both new and existing investors.
The company intends to use the funds to support the Phase II clinical trial of ABT-301 in combination with PD-1 inhibitors for treating microsatellite stable (MSS) metastatic colorectal cancer, which accounts for 95% of the metastatic colorectal cancer population that does not benefit from immune checkpoint inhibitors.
Founded by Dr. Joe Shih, Anbogen is a clinical-stage biotechnology company dedicated to developing precision anti-cancer drugs and is committed to R&D innovations to improve the lives of cancer patients around the world. Two of its drugs, ABT-101 for non-small cell lung cancer (NSCLC) with HER2 exon20 insertion mutations and ABT-301(combine with immune checkpoint inhibitors) for metastatic colorectal cancer, are currently in human clinical trials.
FinSMEs
01/07/2024